Novus Health Services, Inc.

novushs.com

Our goal is to focus on the root of why hospice care began in this country-quality of life. Specifically we provide personalized care to ensure our patients get the most out of their days, weeks, months or years – spending worthwhile time doing what makes them happy – however they want to do it. Most importantly we ensure our patients are pain free and as comfortable as possible throughout their life. We do not believe it is our place to dictate how a patient chooses to live. Patients have the right to remain active and alert and present despite any illness they may have.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

INTRAVACC ANNOUNCES ADDITIONAL FAVORABLE PRECLINICAL AND TOXICOLOGY DATA FOR AVACC 10®, AN INTRANASAL SARS-COV-2 CANDIDATE VACCINE

Intravacc | September 12, 2022

news image

Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine. These results demonstrate a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern. and a good safety profile, allowing progression towards a phase I clinical study. ...

Read More

Cell and Gene Therapy

BIOMARIN AND SKYLINE THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL GENE THERAPIES FOR CARDIOVASCULAR DISEASES

BioMarin Pharmaceutical Inc. | December 17, 2021

news image

BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...

Read More

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

news image

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More

Medical, Industry Outlook

GINKGO BIOWORKS AND THE GOVERNMENT OF THE REPUBLIC OF PANAMA ANNOUNCE PLANS TO ESTABLISH NEW BIOSECURITY CAPABILITIES

PRNewswire | August 07, 2023

news image

Ginkgo Bioworks the leading horizontal platform for cell programming and biosecurity, and the Government of the Republic of Panama's Gorgas Memorial Institute for Health Studies, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Latin America. Ginkgo, through its biosecurity and public health unit, Concentric by Ginkgo, aims to support the Gorgas Institute as it...

Read More
news image

Cell and Gene Therapy

INTRAVACC ANNOUNCES ADDITIONAL FAVORABLE PRECLINICAL AND TOXICOLOGY DATA FOR AVACC 10®, AN INTRANASAL SARS-COV-2 CANDIDATE VACCINE

Intravacc | September 12, 2022

Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine. These results demonstrate a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern. and a good safety profile, allowing progression towards a phase I clinical study. ...

Read More
news image

Cell and Gene Therapy

BIOMARIN AND SKYLINE THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL GENE THERAPIES FOR CARDIOVASCULAR DISEASES

BioMarin Pharmaceutical Inc. | December 17, 2021

BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...

Read More
news image

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More
news image

Medical, Industry Outlook

GINKGO BIOWORKS AND THE GOVERNMENT OF THE REPUBLIC OF PANAMA ANNOUNCE PLANS TO ESTABLISH NEW BIOSECURITY CAPABILITIES

PRNewswire | August 07, 2023

Ginkgo Bioworks the leading horizontal platform for cell programming and biosecurity, and the Government of the Republic of Panama's Gorgas Memorial Institute for Health Studies, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Latin America. Ginkgo, through its biosecurity and public health unit, Concentric by Ginkgo, aims to support the Gorgas Institute as it...

Read More